Ignite Creation Date:
2025-12-24 @ 12:32 PM
Ignite Modification Date:
2026-05-18 @ 5:03 AM
Study NCT ID:
NCT01449461
Status:
COMPLETED
Last Update Posted:
2021-08-17
First Post:
2011-09-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
Sponsor:
Ariad Pharmaceuticals
Organization: